Fera Pharmaceuticals is pleased to announce the launch of Sulfacetamide Sodium Ophthalmic Ointment USP, 10%.
Indicated for superficial ocular infections, including conjunctivitis, Sulfacetamide, in ointment form, will be an important addition to physicians' treatment armamentarium.
David Cobb, VP of Ophthalmics at Fera says "Fera recognized the need to bring Sulfacetamide Ointment to the market. While doctors have access to Sulfacetamide eye drops, ointments have the advantage of maintaining eye contact time longer, particularly in pediatric patients whose tears may inadvertently wash drops out from the eye. In addition, Sulfacetamide ointment is an important treatment adjunct to the solution, especially at nighttime."
"Bringing Sulfacetamide Sodium Ophthalmic Ointment to market is very much in keeping with Fera's vision" says Frank DellaFera, President. "There were other such products available years ago, but their manufacturers decided to discontinue them. We listened to the marketplace and brought it back!"
Advanced sequencing reveals eye microbiome variances linked to dry eye